The Science

The clinical development of psychedelic therapies follows the same rigorous pathway as any other pharmaceutical — preclinical research, Phase I safety trials, Phase II dose-finding studies, and large-scale Phase III confirmatory trials. What makes psychedelic therapy development unusual is the nature of the intervention itself: these are not pills you take at home, but guided therapeutic experiences that combine a pharmacological agent with structured psychological support.

This distinction has profound implications for how trials are designed, how outcomes are measured, and how regulatory agencies evaluate the evidence. A psilocybin session typically lasts 6–8 hours and requires trained therapists, a carefully prepared setting, and follow-up integration sessions. MDMA-assisted therapy for PTSD involves multiple preparatory and integration sessions alongside 2–3 medicine sessions. These are complex interventions that don't fit neatly into the standard drug development playbook.

The evidence base, while still growing, is striking. Psilocybin has shown large effect sizes in trials for treatment-resistant depression and major depressive disorder, with some studies reporting response rates above 70%. MDMA-assisted therapy for PTSD has demonstrated remission rates that far exceed those of existing treatments. Meanwhile, early-stage research is exploring ketamine, LSD, DMT, ibogaine, and 5-MeO-DMT for a range of indications.

But clinical promise does not automatically translate into regulatory approval. Agencies like the FDA and EMA require not just efficacy data, but evidence of safety, manufacturing consistency, and — increasingly — real-world applicability. The challenge of blinding in psychedelic trials (participants often know whether they received the active substance) has led to methodological debates that could influence how regulators weigh the evidence.

In this section, we break down the clinical development pipeline substance by substance, examine the key trials that are shaping the field, and explore the methodological questions that researchers and regulators are grappling with. We draw directly on the research papers in the Blossom database to provide in-depth analysis of what the science actually shows — and where the gaps remain.